List of Excipients in Branded Drug OXYCODONE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	BUTYLATED HYDROXYTOLUENE
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	HYDROXYPROPYL CELLULOSE
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	HYPROMELLOSES
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	MAGNESIUM STEARATE
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	POLYETHYLENE GLYCOL
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	POLYETHYLENE GLYCOL 400

Generic Drugs Containing OXYCODONE

Company	Ingredient	NDC	Excipient
Ascend Laboratories LLC	oxycodone	67877-623	ACACIA
Ascend Laboratories LLC	oxycodone	67877-623	ANHYDROUS CITRIC ACID
Ascend Laboratories LLC	oxycodone	67877-623	CITRIC ACID MONOHYDRATE
Ascend Laboratories LLC	oxycodone	67877-623	FD&C RED NO. 40
Ascend Laboratories LLC	oxycodone	67877-623	GLYCERIN
Ascend Laboratories LLC	oxycodone	67877-623	POLOXAMER 188

What are the Most Frequently-Used Excipients in OXYCODONE?

# Of NDCs	Excipient
1	ACACIA
2	ANHYDROUS CITRIC ACID
1	BERRY
1	CITRIC ACID MONOHYDRATE
1	D&C YELLOW NO. 10
1	FD&C RED NO. 40

Oxycodone Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Oxycodone is a mature controlled-substance market with limited opportunity in conventional immediate-release tablets and stronger opportunities in abuse-deterrent delivery, extended-release formulations, oral liquids, pediatric-friendly products, and manufacturing platforms that reduce opioid misuse. Excipient selection determines release rate, tamper resistance, dose uniformity, swallowability, stability, and the ability to support differentiated regulatory and patent positions.

The most commercially defensible strategy is a platform that combines oxycodone hydrochloride with a reproducible abuse-deterrent matrix, multiparticulate delivery system, or clinically useful liquid formulation. Commodity excipients for standard oxycodone tablets remain price-sensitive and face extensive generic competition.

What excipients are used in oxycodone products?

Oxycodone products use excipients for compression, binding, disintegration, lubrication, coating, taste masking, suspension, controlled release, and abuse deterrence.

Product category	Typical dosage form	Main excipient functions	Commercial position
Immediate-release oxycodone	Tablet, capsule, oral solution	Compression, disintegration, lubrication, taste and viscosity control	Low differentiation
Extended-release oxycodone	Matrix tablet or multiparticulate capsule	Drug release control, mechanical resistance, extraction resistance	Higher regulatory and IP value
Abuse-deterrent oxycodone	Matrix tablet, coated tablet, microspheres	Crush resistance, gelling, reduced solvent extraction, nasal-abuse deterrence	Strongest formulation opportunity
Pediatric or geriatric liquid	Oral solution or suspension	Sweetening, viscosity, preservative system, taste masking	Niche commercial opportunity
Combination product	Oxycodone with naloxone or another active ingredient	Chemical compatibility, release synchronization, taste and stability	Higher clinical and regulatory complexity

Common excipient classes include microcrystalline cellulose, lactose, starches, povidone, crospovidone, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, polyethylene oxide, polyvinyl alcohol, polyethylene glycol, methacrylate copolymers, waxes, lipids, sweeteners, flavoring agents, and preservatives.

Exact excipient composition varies by product and is controlled by the approved labeling, manufacturing process, and regulatory filing. A formulation that uses the same excipient class as an incumbent may still create infringement or regulatory risk if its concentration, processing method, particle engineering, coating architecture, or release profile falls within a protected claim.

Which oxycodone formulations offer the strongest commercial opportunity?

Abuse-deterrent extended-release and immediate-release products offer the highest formulation value.

Abuse-deterrent extended-release oxycodone

OxyContin is an extended-release oxycodone hydrochloride tablet. Purdue Pharma’s reformulated product uses a proprietary tablet matrix intended to resist crushing and to reduce abuse by injection or snorting. The FDA approved the reformulated product in 2010 and later classified it as having abuse-deterrent properties under the FDA’s product-specific guidance framework.[1,2]

Xtampza ER uses DETERx technology, which places oxycodone hydrochloride in microspheres contained in a capsule. The product can be administered intact or sprinkled on soft food under the prescribing information. Its formulation is designed to maintain extended release after physical manipulation and to reduce drug extraction using commonly available solvents.[3]

For excipient suppliers and formulation developers, the relevant opportunity is not simply a harder tablet. A commercially meaningful platform must demonstrate:

• Release-rate retention after crushing, chewing, or grinding
• Reduced extraction in aqueous and alcoholic solvents
• Resistance to conversion into an injectable or snortable preparation
• Consistent pharmacokinetics after administration with food
• Acceptable dissolution under physiological conditions
• Scalable manufacturing with narrow content-uniformity limits
• Evidence that supports FDA abuse-deterrent labeling

Polyethylene oxide, high-viscosity polymers, wax-lipid matrices, coated multiparticulates, and combination polymer systems are potential technology classes. The best choice depends on the target route of abuse, dose strength, manufacturing process, and desired release profile.

Abuse-deterrent immediate-release oxycodone

Oxaydo is an immediate-release oxycodone hydrochloride tablet with labeling describing abuse-deterrent properties for intranasal abuse.[4] RoxyBond was approved in 2017 as an immediate-release oxycodone hydrochloride tablet with abuse-deterrent properties.[5]

Immediate-release abuse-deterrent products create a different formulation problem from extended-release products. The developer must preserve rapid therapeutic onset while limiting particle pulverization, nasal insufflation, or solvent manipulation. Excessive matrix strength can delay dissolution or create dose dumping concerns. The commercial design target is therefore selective resistance, not maximal hardness.

What excipient strategies are available for oxycodone?

Matrix systems

Hydrophilic matrix systems use polymers that hydrate, swell, and form a gel layer. The gel controls water penetration and drug diffusion. High-viscosity polyethylene oxide and hypromellose are established options for extended-release products.

Key development variables include polymer molecular weight, polymer loading, particle size, compression force, tablet porosity, and the interaction between polymer hydration and oxycodone solubility. A matrix with insufficient mechanical strength may be easily crushed. A matrix with excessive polymer content may produce unacceptable food effects or incomplete release.

Multiparticulate systems

Multiparticulate products use coated pellets or drug-loaded microspheres. They can improve dose uniformity and permit sprinkle administration, but the coating process adds cost and process complexity.

Multiparticulates are commercially attractive when they provide:

• Administration flexibility for patients who cannot swallow tablets
• Reduced dose dumping after physical manipulation
• Better control of release through coating thickness
• Lower dependence on a single compressed tablet structure
• Potential protection for particle-engineering and coating patents

The principal risks are coating variability, solvent exposure during manufacture, capsule filling costs, and the need to demonstrate consistent release across multiple particle populations.

Lipid and wax systems

Hydrophobic matrices can reduce water penetration and make extraction more difficult. Waxes, fatty acids, glyceryl esters, and other lipids may improve mechanical resistance and slow dissolution.

These systems require careful control of polymorphism, melting behavior, tablet hardness, and food effects. A lipid matrix can also complicate scale-up and may require a manufacturing process that is more expensive than conventional direct compression.

Coating-based systems

Functional polymer coatings can provide controlled release, taste masking, or mechanical resistance. Coatings may use aqueous or organic processes, depending on the polymer and manufacturing design.

The commercial value of a coating platform increases when it supports multiple oxycodone strengths without a separate formulation for each strength. This can reduce development cost and simplify manufacturing validation.

Liquid and taste-masked systems

Oxycodone oral solutions are useful for patients with swallowing difficulties and for dose titration. The main excipient challenges are taste, preservative compatibility, microbial control, dosing-device accuracy, and accidental pediatric exposure.

A commercial liquid product can differentiate through:

• Sugar-free formulation
• Alcohol-free formulation
• Low-viscosity dosing
• Improved taste masking
• Unit-dose packaging
• Child-resistant and senior-friendly delivery systems
• Reduced sorbitol or propylene glycol content where clinically relevant

Liquid products carry a high diversion and accidental-ingestion risk because the active ingredient is already solubilized. Packaging, concentration selection, and dispensing controls therefore have commercial and regulatory importance.

How does excipient strategy affect FDA approval?

FDA review of an oxycodone formulation focuses on quality, bioequivalence or clinical pharmacology, abuse-deterrent performance where claimed, stability, manufacturing controls, and controlled-substance safeguards.

For a generic immediate-release product, the commercial route is usually an abbreviated new drug application. The formulation must meet bioequivalence requirements and comply with inactive-ingredient limitations. A novel excipient or materially different route of administration can create additional regulatory work.

For an extended-release or abuse-deterrent product, the development burden is higher. FDA’s abuse-deterrent guidance evaluates physical and chemical manipulation, in vitro extraction, pharmacokinetic effects, and, in some cases, human abuse-potential studies.[2]

An excipient strategy that changes release behavior can affect:

• Cmax and Tmax
• Total oxycodone exposure
• Food effects
• Dose proportionality
• Interpatient variability
• Withdrawal or breakthrough-pain risk
• Labeling for crushing, chewing, sprinkling, and administration with food

An excipient should not be selected solely because it is listed as generally recognized as safe in another dosage form. The relevant issue is the proposed route, dose, concentration, duration of exposure, patient population, and formulation context.

What patents protect oxycodone formulations?

The strongest oxycodone patent positions generally protect formulation architecture, abuse-deterrent performance, release profiles, manufacturing processes, or methods of use rather than the oxycodone molecule itself.

Formulation patents

Potential claim categories include:

• Polymer matrix composition
• Drug-loaded microspheres
• Coating layers and coating thickness
• Resistance to crushing or extraction
• Controlled-release dissolution profiles
• Specific oxycodone-to-excipient ratios
• Food-effect mitigation
• Sprinkle administration
• Manufacturing conditions that produce the dosage form

OxyContin, Xtampza ER, Oxaydo, and RoxyBond have different formulation and labeling profiles. Patent analysis must therefore be product-specific and based on the current FDA Orange Book, issued patents, terminal disclaimers, patent-term adjustments, pediatric extensions, and litigation records.[6]

Method-of-use patents

Method-of-use claims may cover treatment of pain, dosing intervals, administration to specific patient populations, or use of an abuse-deterrent formulation. Their commercial value depends on whether the use is reflected in FDA-approved labeling and whether the claims can be enforced against a generic label.

For generic entry, a Paragraph IV certification can challenge listed patents. A generic sponsor may also submit a section viii statement that omits a patented method of use where the remaining labeling supports marketing. The commercial outcome depends on the patent claims, the proposed label, and the litigation result.

Manufacturing and process patents

Manufacturing patents may cover hot-melt processing, polymer dispersion, microsphere formation, coating conditions, particle-size control, or solvent-removal steps. These patents can create a barrier even where the final product composition is outside a competitor’s formulation claims.

Process patents have particular relevance for contract manufacturers. A developer may avoid a composition claim but still infringe a process claim if it uses the same temperature profile, granulation sequence, coating method, or particle-engineering step.

What is the Orange Book status of major oxycodone products?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information.[6] Oxycodone products should be reviewed individually because patents may attach to a specific strength, dosage form, formulation, or approved use.

Product	Active ingredient	Dosage form	Principal differentiation
OxyContin	Oxycodone hydrochloride	Extended-release tablet	Abuse-deterrent matrix
Xtampza ER	Oxycodone hydrochloride	Extended-release capsule with microspheres	Abuse-deterrent multiparticulate technology
Oxaydo	Oxycodone hydrochloride	Immediate-release tablet	Intranasal abuse-deterrent design
RoxyBond	Oxycodone hydrochloride	Immediate-release tablet	Abuse-deterrent formulation
Generic oxycodone	Oxycodone hydrochloride	Tablet, capsule, solution	Price and supply competition

FDA-approved abuse-deterrent labeling does not mean that a product cannot be abused. It means the dosage form has properties intended to make certain forms of manipulation more difficult or less rewarding. The label does not eliminate overdose, diversion, or oral misuse risk.[2]

When does oxycodone lose exclusivity?

Oxycodone hydrochloride itself is long off-patent. Generic immediate-release tablets, capsules, and solutions are widely available. The remaining exclusivity value lies in branded formulation technology, approved abuse-deterrent claims, differentiated delivery systems, and product-specific patents.

Generic entry can occur through several routes:

1. A generic sponsor markets a conventional immediate-release product after satisfying ANDA requirements.
2. A sponsor files a Paragraph IV certification against listed patents.
3. A sponsor omits a patented method of use through a section viii statement.
4. A competing brand launches a distinct formulation with its own clinical and regulatory package.
5. A product loses commercial protection even before every patent expires because prescribers and payers shift toward lower-cost alternatives.

Patent expiration dates should be calculated from the specific patent’s effective term, not from the original oxycodone approval date. Patent-term adjustment, pediatric exclusivity, terminal disclaimers, reissued patents, and settlement agreements can change the practical entry date.

Which companies are challenging oxycodone products?

The generic oxycodone market includes major manufacturers such as Teva, Mallinckrodt, Rhodes Pharmaceuticals, Hikma, Amneal, Dr. Reddy’s Laboratories, and other approved suppliers. Participation varies by dosage form, strength, manufacturing site, supply status, and current FDA approval status.

The most important competitive distinction is between:

• Low-cost conventional oxycodone products
• Authorized or branded generic products
• Abuse-deterrent formulations
• Extended-release products
• Oral solutions and specialized dosage forms

Generic competition is strongest in standard immediate-release tablets. The barrier is higher for products requiring multiparticulate manufacturing, specialized polymers, abuse-deterrent testing, or a proprietary delivery system.

What commercial opportunities exist for excipient suppliers?

High-value opportunity areas

Excipient suppliers can create more defensible value in the following areas:

Opportunity	Technical requirement	Commercial attractiveness
Crush-resistant matrix	High mechanical strength with acceptable dissolution	High
Solvent-resistant formulation	Reduced extraction in water, alcohol, and mixed solvents	High
Multiparticulate platform	Uniform drug loading and reproducible coating	High
Sprinkle formulation	Stable release after administration with soft food	Medium to high
Taste-masked liquid	Palatability without compromising stability	Medium
Low-cost generic matrix	Direct compression and robust scale-up	Medium
Child-resistant liquid system	Accurate dosing and controlled access	Medium
Multifunctional excipient	Binding, release control, and abuse deterrence in one system	High

The most attractive supplier proposition is a qualified excipient system with regulatory documentation, formulation know-how, and process support. A single raw material has limited pricing power unless it provides a measurable advantage in abuse-deterrent performance, bioavailability, manufacturability, or stability.

Licensing and partnership opportunities

Licensing opportunities may arise around:

• Abuse-deterrent polymer matrices
• Drug-loaded microspheres
• Tablet-hardening technologies
• Solvent-resistant excipient combinations
• Taste-masking systems
• Continuous manufacturing methods
• Platform technologies adaptable to hydromorphone, morphine, hydrocodone, and other controlled substances

The strongest deal structures will typically link payments to formulation milestones, FDA acceptance, approval, and commercial supply rather than rely only on upfront licensing revenue. Controlled-substance handling capability and an established DEA-compliant manufacturing network can materially increase the value of a technology partner.

How strong is the oxycodone patent estate?

The patent estate is strongest around proprietary extended-release and abuse-deterrent delivery systems. It is weak around the oxycodone active ingredient and conventional immediate-release tablets.

Patent strength depends on:

• Claim scope around the complete formulation
• Ability to prove infringement from public product information
• Validity over prior controlled-release and abuse-deterrent technologies
• Whether the patent is listed in the Orange Book
• Remaining patent term
• FDA-approved labeling overlap
• Availability of non-infringing formulation alternatives
• Manufacturing complexity required to design around the claims

A broad polymer claim may be commercially valuable but vulnerable to prior art. A narrower claim covering a specific extraction-resistance profile may be harder to design around but may also be easier to challenge on validity or infringement grounds. The best estate combines composition, process, performance, and method-of-use claims.

What generic launch scenarios exist for oxycodone?

Conventional immediate-release launch

This is the lowest-barrier scenario. Competition is based on price, manufacturing reliability, wholesaler access, controlled-substance quota management, and supply continuity.

Extended-release design-around

A generic or follow-on sponsor may develop a formulation with a different polymer system, particle structure, or release mechanism. The sponsor must address bioequivalence, food effects, dose dumping, and any listed formulation patents.

Abuse-deterrent follow-on

A sponsor may seek approval for an abuse-deterrent product that does not copy the branded formulation. This requires substantial in vitro testing and may require clinical abuse-potential studies. The commercial return depends on payer acceptance, prescriber confidence, and whether the product receives meaningful formulary preference.

Authorized generic or settlement launch

A patent settlement may establish a future launch date, authorized generic arrangement, supply agreement, or license. Settlement terms can change the competitive landscape without immediately eliminating the branded product’s commercial position. The relevant evidence is found in court filings, FTC reviews where applicable, and public company disclosures.

What revenue exposure does oxycodone create?

Revenue exposure is concentrated in branded extended-release products and differentiated abuse-deterrent formulations. Standard immediate-release oxycodone is exposed to extensive generic substitution and price erosion.

The principal commercial risks are:

• Generic substitution
• Opioid prescribing restrictions
• State and federal enforcement actions
• Payer preference for non-opioid therapies
• Declining chronic-pain use
• Product recalls or manufacturing interruptions
• Controlled-substance quota limits
• Reputational and litigation exposure
• Physician reluctance to prescribe long-acting opioids

Excipient technology can improve differentiation but cannot eliminate demand-side risks. A formulation investment is most defensible when it solves a defined clinical or regulatory problem, such as administration flexibility, extraction resistance, dose titration, or reduced food-effect variability.

Key Takeaways

• Conventional oxycodone tablets are mature, low-margin products with extensive generic competition.
• Abuse-deterrent extended-release systems offer the strongest formulation and licensing opportunities.
• Multiparticulate capsules, solvent-resistant matrices, and crush-resistant tablets have higher technical and IP value.
• Liquid oxycodone products offer niche opportunities in taste masking, dosing accuracy, packaging, and pediatric or geriatric administration.
• Oxycodone’s active ingredient is off-patent; remaining exclusivity is concentrated in formulation, process, and method-of-use claims.
• FDA abuse-deterrent labeling requires evidence tied to specific manipulation routes and does not mean the product is abuse-proof.
• Excipient suppliers gain the most leverage from integrated formulation platforms supported by regulatory files, scale-up data, and controlled-substance manufacturing expertise.
• Generic launch risk is highest for immediate-release products and more complex for extended-release and abuse-deterrent products.

FAQs

Can a new excipient create market exclusivity for oxycodone?

A new excipient alone does not create exclusivity. Protection may arise when the excipient is claimed as part of a novel formulation, manufacturing process, release profile, or abuse-deterrent performance characteristic.

Are polyethylene oxide polymers suitable for oxycodone abuse-deterrent formulations?

They can be suitable for hydrophilic matrix systems, but suitability depends on molecular weight, concentration, compression behavior, dissolution, extraction resistance, and pharmacokinetic performance.

Does an abuse-deterrent oxycodone formulation prevent overdose?

No. Abuse-deterrent properties target specific manipulation routes and do not prevent overdose from oral administration, excessive dosing, drug interactions, or misuse.

Is oxycodone oral solution a major commercial growth segment?

It is a specialized segment rather than a broad growth market. Opportunities are strongest in taste masking, accurate dosing, packaging, alcohol-free systems, and formulations designed for patients unable to swallow tablets.

What is the most valuable excipient capability for an oxycodone licensee?

The highest-value capability is a scalable, well-characterized platform that combines mechanical abuse resistance, reduced solvent extraction, acceptable pharmacokinetics, and a patent position that can be applied across controlled-release opioid products.

References

1. U.S. Food and Drug Administration. (2010). FDA approves new formulation of OxyContin. https://www.fda.gov
2. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov
3. U.S. Food and Drug Administration. (2016). Xtampza ER prescribing information. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2012). Oxaydo prescribing information. https://www.accessdata.fda.gov
5. U.S. Food and Drug Administration. (2017). FDA approves RoxyBond with abuse-deterrent properties. https://www.fda.gov
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov